August and September 2021 FDA drug approvals include treatments for tick-borne encephalitis, idiopathic hypersomnia, schizophrenia, and atopic dermatitis.
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
Individuals with psoriasis/PsA have decreased ability to participate in social roles and activities, more depression symptoms.
At AAD VMX 2021, researchers presented data on skin clearance rates through 5 years with guselkumab in patients with moderate to severe plaque psoriasis.
In moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to data from 2 studies.
Researchers sought to determine if a higher cumulative pain intensity is associated with premature mortality risk in patients with PsA.
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
Real-world data from patients with plaque psoriasis treated with guselkumab, who had previously been administered biologic agents is presented.
A novel study evaluated the effect of cardiometabolic syndrome on early vascular disease in patients with psoriasis.
The correlation between physician-evaluated PASI and BSA involvement and patient-evaluated DLQI and PDI was evaluated in measuring psoriasis disease severity.
Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.
The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported.
Researchers determined the causal associations between genetically predicted TNF-α, IL-12p70, and IL-17 levels and risk for psoriatic arthritis.
Researchers compared the effect of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function.
A roundtable discussion by experts in issues facing patients with skin of color reveals interesting insights.
For adults with psoriatic diseases, the likelihood of developing bone fractures is increased, although they have no increased risk for osteoporosis.
The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study.
Researchers evaluated the association between fibromyalgia in psoriatic arthritis and enthesopathy, sleep, fatigue, and quality of life.
Researchers assessed the prevalence of pharmacologically treated depression among individuals with and without psoriasis.
The relationship of palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque psoriasis were examined.